Skip to content
TrialScanner

NCT01861496

Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours

Phase 1/Phase 2CompletedALLRLead

Registry record

Lead sponsor
Allarity Therapeutics
Conditions
Phase 1: Advanced or Refractory Solid Tumours; Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer
Primary completion
Oct 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT01861496 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.